Okawa-Takatsuji Masako, Nagatani Katsuya, Nakajima Kyoichi, Itoh Kenji, Kano Toshikazu, Nagashio Chiaki, Takahashi Yuko, Aotsuka Shinichi, Mimori Akio
Department of Community Health and Medicine, Research Institute, International Medical Center of Japan, Tokyo, Japan.
J Clin Apher. 2007;22(6):323-9. doi: 10.1002/jca.20155.
The objective of this study is to evaluate the cellular mechanism underlying filtration leukocytapheresis (LCAP) therapy for the treatment of rheumatoid arthritis (RA). Thirteen patients with refractory RA each underwent three sessions of LCAP. Before (pre-) and after (post-) the completion of the first LCAP session, peripheral blood was sampled and analyzed for neutrophil surface markers using flow cytometry. The surface antigens of peripheral blood mononuclear cells (PBMCs) and neutrophils obtained at pre- and post-LCAP were then analyzed using a fluorescence-activated cell sorter. The American College of Rheumatology's criterion of a 20% improvement was achieved in six patients, but not in the other seven patients, after LCAP therapy. The post-LCAP number of blood band form neutrophils with a bone marrow phenotype (CD49d(dim+), low density) was higher among the responders than among the nonresponders, suggesting an association between the clinical response and the recruitment of bone-marrow-derived neutrophils. After the nonspecific absorption of WBCs during a 1-h Cellsorba procedure, the number of PBMCs was consistently decreased, although the number of neutrophils that were affected by removal plus recruitment varied in a manner that was independent of efficacy. In contrast, the emergence of immature neutrophils in the peripheral blood was characteristic of the effective therapies. These cells were found after the 1st session of responders and also found following sessions of LCAPs. Immature neutrophils, which may be recruited from the bone marrow in the peripheral blood after the first session of LCAP, can predict the clinical efficacy of subsequent LCAP sessions.
本研究的目的是评估用于治疗类风湿关节炎(RA)的过滤白细胞去除术(LCAP)疗法的细胞机制。13例难治性RA患者均接受了3个疗程的LCAP治疗。在第一次LCAP疗程完成前(治疗前)和后(治疗后),采集外周血并使用流式细胞术分析中性粒细胞表面标志物。然后使用荧光激活细胞分选仪分析LCAP治疗前后获得的外周血单个核细胞(PBMC)和中性粒细胞的表面抗原。LCAP治疗后,6例患者达到了美国风湿病学会20%改善标准,但其他7例患者未达到。有反应者治疗后具有骨髓表型(CD49d(dim+),低密度)的血杆状核中性粒细胞数量高于无反应者,提示临床反应与骨髓来源中性粒细胞的募集之间存在关联。在1小时的血细胞吸附过程中白细胞进行非特异性吸附后,PBMC数量持续减少,尽管受去除和募集影响的中性粒细胞数量以与疗效无关的方式变化。相比之下,外周血中出现未成熟中性粒细胞是有效治疗的特征。这些细胞在有反应者的第一个疗程后出现,也在后续的LCAP疗程后出现。第一次LCAP疗程后可能从骨髓募集到外周血中的未成熟中性粒细胞可以预测后续LCAP疗程的临床疗效。